Immune therapy in sepsis: Are we ready to try again?

Journal of the Intensive Care Society

Volumn 19, Issue 4, 2018, Pages 326-344

  Davies, Roger ^a,b   O’Dea, Kieran ^a   Gordon, Anthony ^a,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

adjuvant immune therapy; immune biomarker; immune suppression; Sepsis; sepsis immune pathogenesis

Indexed keywords

ALBUMIN; B7 ANTIGEN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD135 ANTIGEN; CD28 ANTIGEN; CD74 ANTIGEN; CD86 ANTIGEN; CREATININE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NIVOLUMAB; PLASMA PROTEIN; PROCALCITONIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; ANTIGEN PRESENTING CELL; CATABOLISM; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CLINICAL TRIAL (TOPIC); DISEASE BURDEN; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTOPENIA; METABOLIC SYNDROME X; MULTIPLE ORGAN FAILURE; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME; WOUND HEALING;

EID: 85045032633     PISSN: 17511437     EISSN: None     Source Type: Journal    
DOI: 10.1177/1751143718765407     Document Type: Review

References (170)

1. Singer M, Deutschman CS, Seymour CW, The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315: 801–810
2. Vincent J-L, Sakr Y, Sprung CL, Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344–353
3. Daniels R (ed.), Nutbeam T (ed.). The Sepsis Manual. Birmingham: United Kingdom Sepsis Trust; 2017. Available from https://sepsistrust.org/wp-content/uploads/2018/02/Sepsis_Manual_2017_web_download.pdf (2017, accessed 9 March 2018)
4. Cavaillon JM, Eisen D, Annane D. Is boosting the immune system in sepsis appropriate? Crit Care 2014; 18: 216
5. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med 2014; 20: 195–203
6. Boomer JS, Green JM, Hotchkiss RS. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? Virulence 2014; 5: 45–56
7. Levy MM, Rhodes A, Annane D, Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580–637
8. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. The review on antimicrobial resistance, https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf (2016, accessed 5 February 2018)
9. Bo L, Wang F, Zhu J, Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care 2011; 15: R58
10. Clark IA. The advent of the cytokine storm. Immunol Cell Biol 2007; 85: 271–273
11. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24: 1125–1128
12. Gomez HG, Gonzalez SM, London JM, et al. Immunological characterization of compensatory anti-inflammatory response syndrome in patients with severe sepsis. Crit Care Med 2014; 42: 771–780
13. Cavaillon JM. “Septic Plasma”: an immunosuppressive milieu. Am J Respir Crit Care Med 2002; 166: 1417–1418
14. Hotchkiss RS, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009; 15: 496–497
15. Davenport EE, Burnham KL, Radhakrishnan J, Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 2016; 4: 259–271
16. Tang BM, Huang SJ, McLean AS. Genome-wide transcription profiling of human sepsis: a systematic review. Crit Care 2010; 14: R237
17. Cavaillon JM, Adrie C, Fitting C, Reprogramming of circulatory cells in sepsis and SIRS. J Endotoxin Res 2005; 11: 311–320
18. Volk H-D, Reinke P, Krausch D, Monocyte deactivation–rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996; 22(Suppl 4): S474–S481
19. Arens C, Bajwa SA, Koch C, Sepsis-induced long-term immune paralysis–results of a descriptive, explorative study. Crit Care 2016; 20: 93
20. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013; 13: 862–874
21. Boomer JS, Faist E, Wichmann M, Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306: 2594–2605
22. Torgersen C, Moser P, Luckner G, Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg 2009; 108: 1817–1841
23. Gentile LF, Cuenca AG, Efron PA, Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg 2012; 72: 1491–1501
24. Mira JC, Gentile LF, Mathias BJ, Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome. Crit Care Med 2017; 45: 253–262
25. Busani S, Serafini G, Mantovani E, Mortality in patients with septic shock by multidrug resistant bacteria. J Intensive Care Med 2017. Epub ahead of print 18 January 2017. DOI: 10.1177/088506661668816
26. Wolk K, Döcke WD, Baehr von V, Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 2000; 96: 218–223
27. Le Tulzo Y, Pangault C, Amiot L, Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock. Am J Respir Crit Care Med 2004; 169: 1144–1151
28. Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 2006; 10: 233
29. Monneret G, Lepape A, Voirin N, Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006; 32: 1175–1183
30. Lukaszewicz A-C, Grienay M, Resche-Rigon M, Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit Care Med 2009; 37: 2746–2752
31. Monneret G, Debard A-L, Venet F, Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med 2003; 31: 2068–2071
32. Nascimento DC, Alves-Filho JC, Sônego F, Role of regulatory T cells in long-term immune dysfunction associated with severe sepsis. Crit Care Med 2010; 38: 1718–1725
33. Delano MJ, Scumpia PO, Weinstein JS, MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007; 204: 1463–1474
34. Chang K, Svabek C, Vazquez-Guillamet C, Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care 2014; 18: R3
35. Newton S, Ding Y, Chung C-S, Sepsis-induced changes in macrophage co-stimulatory molecule expression: CD86 as a regulator of anti-inflammatory IL-10 response. Surg Infect 2004; 5: 375–383
36. Conway Morris A, Kefala K, Wilkinson TS, C5a mediates peripheral blood neutrophil dysfunction in critically ill patients. Am J Respir Crit Care Med 2009; 180: 19–28
37. Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol 2004; 4: 133–142
38. Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med 2006; 34: 15–21
39. Tu W, Rao S. Mechanisms underlying T Cell immunosenescence: aging and cytomegalovirus infection. Front Microbiol 2016; 7: 2111
40. Fisher CJ, Agosti JM, Opal SM, Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334: 1697–1702
41. Calvano SE, Xiao W, Richards DR, A network-based analysis of systemic inflammation in humans. Nature 2005; 437: 1032–1037
42. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001; 29: S121–S125
43. Eichacker PQ, Parent C, Kalil A, Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166: 1197–1205
44. Pierrakos C, Vincent J-L. Sepsis biomarkers: a review. Crit Care 2010; 14: R15
45. Nargis W, Ibrahim M, Ahamed BU. Procalcitonin versus C-reactive protein: Usefulness as biomarker of sepsis in ICU patient. Int J Crit Illn Inj Sci 2014; 4: 195–199
46. O'Grady NP, Barie PS, Bartlett JG, Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med 2008; 36: 1330–1349
47. de Azevedo JRA, Torres OJM, Beraldi RA, Prognostic evaluation of severe sepsis and septic shock: procalcitonin clearance vs Δ Sequential Organ Failure Assessment. J Crit Care 2015; 30: 219.e9–219.e12
48. Sridharan P, Chamberlain RS. The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills? Surg Infect 2013; 14: 489–511
49. Patel RT, Deen KI, Youngs D, Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg 1994; 81: 1306–1308
50. Gogos CA, Drosou E, Bassaris HP, Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000; 181: 176–180
51. Wu H-P, Chen C-K, Chung K, Serial cytokine levels in patients with severe sepsis. Inflamm Res 2009; 58: 385–393
52. Bozza FA, Salluh JI, Japiassu AM, Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007; 11: R49
53. Kofoed K, Schneider UV, Scheel T, Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin Chem 2006; 52: 1284–1293
54. Shapiro NI, Trzeciak S, Hollander JE, A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med 2009; 37: 96–104
55. Bentzer P, Fjell C, Walley KR, Plasma cytokine levels predict response to corticosteroids in septic shock. Intensive Care Med 2016; 42: 1970–1979
56. Zhang X, Morrison DC. Lipopolysaccharide structure-function relationship in activation versus reprogramming of mouse peritoneal macrophages. J Leukoc Biol 1993; 54: 444–450
57. Leentjens J, Kox M, Koch RM, Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med 2012; 186: 838–845
58. Segre E, Fullerton JN. Stimulated whole blood cytokine release as a biomarker of immunosuppression in the critically ill: the need for a standardized methodology. Shock 2016; 45: 490–494
59. Gibot S, Kolopp-Sarda M-N, Béné MC, Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 2004; 141: 9–15
60. Jeong SJ, Song YG, Kim CO, Measurement of plasma sTREM-1 in patients with severe sepsis receiving early goal-directed therapy and evaluation of its usefulness. Shock 2012; 37: 574–578
61. Su L, Liu D, Chai W, Role of sTREM-1 in predicting mortality of infection: a systematic review and meta-analysis. BMJ Open 2016; 6: e010314
62. Döcke WD, Randow F, Syrbe U, Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med 1997; 3: 678–681
63. Nakos G, Malamou-Mitsi VD, Lachana A, Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-γ. Crit Care Med 2002; 30: 1488–1494
64. Demaret J, Walencik A, Jacob M-C, Inter-laboratory assessment of flow cytometric monocyte HLA-DR expression in clinical samples. Cytometry B Clin Cytom 2013; 84: 59–62
65. Meisel C, Schefold JC, Pschowski R, Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009; 180: 640–648
66. Drewry AM, Ablordeppey EA, Murray ET, Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor alpha production as outcome predictors in severe sepsis: a prospective observational study. Crit Care 2016; 20: 334
67. Venet F, Davin F, Guignant C, Early assessment of leukocyte alterations at diagnosis of septic shock. Shock 2010; 34: 358–363
68. Drewry AM, Samra N, Skrupky LP, Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock 2014; 42: 383–391
69. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33: 1974–1982
70. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–264
71. Shao R, Fang Y, Yu H, Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. Crit Care 2016; 20: 124
72. Guignant C, Lepape A, Huang X, Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care 2011; 15: R99
73. Boomer JS, Shuherk-Shaffer J, Hotchkiss RS, A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care 2012; 16: R112
74. Shalova IN, Lim JY, Chittezhath M, Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1α. Immunity 2015; 42: 484–498
75. Peronnet E, Venet F, Maucort-Boulch D, Association between mRNA expression of CD74 and IL10 and risk of ICU-acquired infections: a multicenter cohort study. Intensive Care Med 2017; 111: 778–778
76. Cazalis M-A, Friggeri A, Cavé L, Decreased HLA-DR antigen-associated invariant chain (CD74) mRNA expression predicts mortality after septic shock. Crit Care 2013; 17: R287
77. McHugh L, Seldon TA, Brandon RA, A molecular host response assay to discriminate between sepsis and infection-negative systemic inflammation in critically ill patients: discovery and validation in independent cohorts. PLoS Med 2015; 12: e1001916
78. Burnham KL, Davenport EE, Radhakrishnan J, Shared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumonia. Am J Respir Crit Care Med 2017; 196: 328–339
79. Conway Morris A, Datta D, Shankar-Hari M, Predictive value of cell-surface markers in infections in critically ill patients: protocol for an observational study (ImmuNe FailurE in Critical Therapy (INFECT) Study). BMJ Open 2016; 6: e011326
80. Monneret G, Venet F. Monocyte HLA-DR in sepsis: shall we stop following the flow? Crit Care 2014; 18: 102
81. Cajander S, Bäckman A, Tina E, Preliminary results in quantitation of HLA-DRA by real-time PCR: a promising approach to identify immunosuppression in sepsis. Crit Care 2013; 17: R223
82. Sprung CL, Morales RC, Kasdan H, Diagnosis of infection utilizing Accellix CD64. Intensive Care Med Exp 2015; 3: A1013
83. Sprung CL, Morales RC, Kasdan H, Comparison of cd64 levels performed by the FACS and Accellix systems. Intensive Care Med Exp 2015; 3: A1012
84. Topalian SL, Hodi FS, Brahmer JR, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2454
85. Hotchkiss RS, Moldawer LL. Parallels between cancer and infectious disease. N Engl J Med 2014; 371: 380–383
86. Grimaldi D, Pradier O, Hotchkiss RS, Nivolumab plus interferon-γ in the treatment of intractable mucormycosis. Lancet Infect Dis 2017; 17: 18
87. Leentjens J, Gresnigt MS, van de Veerdonk FL, Adjuvant interferon-gamma immunotherapy in a patient with progressive cerebral Nocardia abscesses. Int J Infect Dis 2017; 59: 25–28
88. Shindo Y, Unsinger J, Burnham C-A, Interleukin 7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression. Shock 2015; 43: 334–343
89. Chang KC, Burnham C-A, Compton SM, Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care 2013; 17: R85
90. Barber DL, Wherry EJ, Masopust D, T cells during chronic viral infection. Nature 2006; 439: 682–687
91. Gardiner D, Lalezari J, Lawitz E, A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 2013; 8: e63818
92. Fuller MJ, Callendret B, Zhu B, Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci USA 2013; 110: 15001–15006
93. D'Errico G, Machado HL, Sainz B. A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet. Clin Transl Med 2017; 6: 3
94. Inoue S, Bo L, Bian J, Dose-dependent effect of anti-CTLA-4 on survival in sepsis. Shock 2011; 36: 38–44
95. Chen J, Ivashkiv LB. IFN-γ abrogates endotoxin tolerance by facilitating Toll-like receptor-induced chromatin remodeling. Proc Natl Acad Sci USA 2010; 107: 19438–19443
96. Smith RP, Baltch AL, Ritz WJ, IFN-γ enhances killing of methicillin-resistant Staphylococcus aureus by human monocytes more effectively than GM-CSF in the presence of daptomycin and other antibiotics. Cytokine 2010; 51: 274–277
97. Randow F, Döcke WD, Bundschuh DS, In vitro prevention and reversal of lipopolysaccharide desensitization by IFN-gamma, IL-12, and granulocyte-macrophage colony-stimulating factor. J Immunol 1997; 158: 2911–2918
98. Kox WJ. Interferon Gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. Arch Intern Med 1997; 157: 389
99. Billiau A, Heremans H, Vandekerckhove F, Anti-interferon-gamma antibody protects mice against the generalized Shwartzman reaction. Eur J Immunol 1987; 17: 1851–1854
100. Turrel-Davin F, Venet F, Monnin C, mRNA-based approach to monitor recombinant gamma-interferon restoration of LPS-induced endotoxin tolerance. Crit Care 2011; 15: R252
101. Mathias B, Szpila BE, Moore FA, A review of GM-CSF therapy in sepsis. Medicine (Baltimore) 2015; 94: e2044
102. Jarvis JN, Meintjes G, Rebe K, Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012; 26: 1105–1113
103. Delsing CE, Gresnigt MS, Leentjens J, Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect Dis 2014; 14: 166
104. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13: 260–268
105. van de Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 2012; 119: 3383–3393
106. Brissette WH, Baker DA, Stam EJ, GM-CSF rapidly primes mice for enhanced cytokine production in response to LPS and TNF. Cytokine 1995; 7: 291–295
107. Shindo J, Ishibashi T, Yokoyama K, Granulocyte-macrophage colony stimulating factor prevents the progression of atherosclerosis via changes in the cellular and extracellular composition of atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits. Circulation 1999; 99: 2150–2156
108. Piguet PF, Grau GE, de Kossodo S. Role of granulocyte-macrophage colony-stimulating factor in pulmonary fibrosis induced in mice by bleomycin. Experimental Lung Res 2009; 19: 579–587
109. Serafini P, Carbley R, Noonan KA, High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64: 6337–6343
110. Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11: 330–342
111. Corfe SA, Paige CJ. The many roles of IL-7 in B cell development; mediator of survival, proliferation and differentiation. Semin Immunol 2012; 24: 198–208
112. Sprent J, Surh CD. Interleukin 7, maestro of the immune system. Semin Immunol 2012; 24: 149–150
113. Levy Y, Lacabaratz C, Weiss L, Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119: 997–1007
114. Pellegrini M, Calzascia T, Elford AR, Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med 2009; 15: 528–536
115. Morre M, Beq S. Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Target Oncol 2012; 7: 55–68
116. Lévy Y, Sereti I, Tambussi G, Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012; 55: 291–300
117. Sportès C, Hakim FT, Memon SA, Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008; 205: 1701–1714
118. Unsinger J, Burnham C-AD, McDonough J, Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J Infect Dis 2012; 206: 606–616
119. Shindo Y, Fuchs AG, Davis CG, Interleukin 7 immunotherapy improves host immunity and survival in a two-hit model of Pseudomonas aeruginosa pneumonia. J Leukoc Biol 2017; 101: 543–554
120. Unsinger J, McGlynn M, Kasten KR, IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol 2010; 184: 3768–3779
121. Kasten KR, Prakash PS, Unsinger J, Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis. Infect Immun 2010; 78: 4714–4722
122. Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005; 174: 6571–6576
123. Levy Y, Lacabaratz C, Weiss L, Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119: 997–1007
124. Sereti I, Dunham RM, Spritzler J, IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113: 6304–6314
125. Sportès C, Babb RR, Krumlauf MC, Phase I study of recombinant human Interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010; 16: 727–735
126. Rosenberg SA, Sportès C, Ahmadzadeh M, IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006; 29: 313–319
127. Wan J, Shan Y, Shan H, Thymosin-alpha1 promotes the apoptosis of regulatory T cells and survival rate in septic mice. Front Biosci 2011; 16: 3004–3013
128. Favalli C, Jezzi T, Mastino A, Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol Immunother 1985; 20: 189–192
129. Giacomini E, Severa M, Cruciani M, Dual effect of Thymosin α 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial toll-like receptor agonists. Expert Opin Biol Ther 2015; 15(Suppl 1): S59–S70
130. Serafino A, Pica F, Andreola F, Thymosin a1 activates complement receptor-mediated phagocytosis in human monocyte-derived macrophages. J Innate Immun 2014; 6: 72–88
131. Wu X, Jia J, You H. Thymosin alpha-1 treatment in chronic hepatitis B. Expert Opin Biol Ther 2015; 15(Suppl 1): S129–S132
132. Sherman KE, Sjogren M, Creager RL, Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 1998; 27: 1128–1135
133. Chan HLY, Tang JL, Tam W, The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmol Ther 2001; 15: 1899–1905
134. Camerini R, Garaci E. Historical review of thymosin α 1 in infectious diseases. Expert Opin Biol Ther 2015; 15(Suppl 1): S117–S127
135. Liu F, Wang H-M, Wang T, The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials. BMC Infect Dis 2016; 16: 488
136. Wu J, Zhou L, Liu J, The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care 2013; 17: R8
137. Endo S, Inada K, Yamashita H, The inhibitory actions of protease inhibitors on the production of polymorphonuclear leukocyte elastase and interleukin 8. Res Commun Chem Pathol Pharmacol 1993; 82: 27–34
138. Inoue K-I, Takano H. Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders. Expert Opin Investig Drugs 2010; 19: 513–520
139. Liu D, Yu Z, Yin J, Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta-analysis of Chinese and Indian patients. J Crit Care 2017; 39: 259–266
140. Shankar-Hari M, Spencer J, Sewell WA, Bench-to-bedside review: Immunoglobulin therapy for sepsis – biological plausibility from a critical care perspective. Crit Care 2012; 16: 206
141. Rhodes A, Evans LE, Alhazzani W, Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med 2017; 43: 304–377
142. Busani S, Damiani E, Cavazzuti I, Intravenous immunoglobulin in septic shock: review of the mechanisms of action and meta-analysis of the clinical effectiveness. Minerva Anestesiol 2016; 82: 559–572
143. Cavazzuti I, Serafini G, Busani S, Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock. Intensive Care Med 2014; 40: 1888–1896
144. Soares MO, Welton NJ, Harrison DA, Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial. Crit Care 2014; 18: 649
145. Gomez A, Wang R, Unruh H, hemofiltration reverses left ventricular dysfunction during sepsis in dogs. Anesthesiology 1990; 73: 671–685
146. Ronco C, Bellomo R, Homel P, Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356: 26–30
147. Cornejo R, Downey P, Castro R, High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 2006; 32: 713–722
148. Honore PM, Jamez J, Wauthier M, Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000; 28: 3581
149. Hara Y, Shimomura Y, Nakamura T, Novel blood purification system for regulating excessive immune reactions in severe sepsis and septic shock: an ex vivo pilot study. Ther Apher Dial 2015; 19: 308–315
150. Kellum JA, Song M, Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 2004; 32: 801–805
151. Peng Z-Y, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med 2008; 36: 1573–1577
152. Sato T, Orlowski JP, Zborowski M. Experimental study of extracorporeal perfusion for septic shock. ASAIO J 1993; 39: M790–M793
153. Cruz DN, Antonelli M, Fumagalli R, Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301: 2445–2452
154. Payen DM, Guilhot J, Launey Y, Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 2015; 41: 975–984
155. Cutuli SL, Artigas A, Fumagalli R, Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry. Ann Intensive Care 2016; 6: 77
156. Klein DJ, Foster D, Schorr CA, The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. Trials 2014; 15: 218
157. Iba T, Fowler L. Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial. J Intensive Care 2017; 5: 40
158. Kogelmann K, Jarczak D, Scheller M, Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care 2017; 21: 74
159. Kang JH, Super M, Yung CW, An extracorporeal blood-cleansing device for sepsis therapy. Nat Med 2014; 20: 1211–1216
160. Didar TF, Cartwright MJ, Rottman M, Improved treatment of systemic blood infections using antibiotics with extracorporeal opsonin hemoadsorption. Biomaterials 2015; 67: 382–392
161. van der Poll T, Jansen J, Endert E, Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood. Infect Immun 1994; 62: 2046–2050
162. McNamee EN, Griffin EW, Ryan KM, Noradrenaline acting at beta-adrenoceptors induces expression of IL-1beta and its negative regulators IL-1ra and IL-1RII, and drives an overall anti-inflammatory phenotype in rat cortex. Neuropharmacology 2010; 59: 37–48
163. Torres KCL, Antonelli LRV, Souza ALS, Norepinephrine, dopamine and dexamethasone modulate discrete leukocyte subpopulations and cytokine profiles from human PBMC. J Neuroimmunol 2005; 166: 144–157
164. Xiu F, Stanojcic M, Jeschke MG. Norepinephrine inhibits macrophage migration by decreasing CCR2 expression. PLoS One 2013; 8: e69167
165. McMahon PJ, Proctor KG. Vasopressin attenuates TNF-mediated inflammation in the rat cremaster microcirculation. J Trauma 2009; 67: 461–473
166. Boyd JH, Holmes CL, Wang Y, Vasopressin decreases sepsis-induced pulmonary inflammation through the V2R. Resuscitation 2008; 79: 325–331
167. Peng T-C, Huang C-J. Vasopressin inhibits endotoxin-induced upregulation of inflammatory mediators in activated macrophages. Tzu Chi Med J 2013; 25: 150–154
168. Davies R, O' Dea KP, Soni S, Vasopressin alone and with noradrenaline attenuates TNF-α production in an in-vitro model of monocyte priming and deactivation. Crit Care 2017; 21: P362
169. Russell JA, Fjell C, Hsu JL, Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. Am J Respir Crit Care Med 2013; 188: 356–364
170. Gordon AC, Mason AJ, Thirunavukkarasu N, Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The VANISH Randomized Clinical Trial. JAMA 2016; 316: 509–518